600 Participants Needed

Geriatric Assessment for Cancer

Recruiting at 4 trial locations
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: City of Hope Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Comprehensive Geriatric Assessment for older patients with cancer?

Research shows that a Comprehensive Geriatric Assessment (CGA) helps in predicting outcomes and making treatment decisions for older cancer patients. It evaluates various health aspects, which can guide interventions to improve cancer care quality and predict potential treatment complications.12345

Is the Comprehensive Geriatric Assessment safe for older adults with cancer?

The Comprehensive Geriatric Assessment is generally considered safe for older adults with cancer, as it helps evaluate their overall health and treatment risks without involving any invasive procedures.16789

How does the geriatric assessment treatment differ from other cancer treatments for older adults?

The geriatric assessment treatment is unique because it involves a comprehensive evaluation of an older adult's medical, psychological, social, and functional capacity, which helps tailor cancer treatment to their specific needs. This approach is different from standard treatments as it aims to improve decision-making and outcomes by considering the complex health issues often present in older patients.12101112

What is the purpose of this trial?

This randomized clinical trial studies a geriatric assessment intervention in predicting chemotherapy toxicity and vulnerabilities (or weakness) in older patients with cancer. Assessing patients' functional status, comorbidities, psychological state, social support, nutritional status, and cognitive function before treatment may help identify vulnerabilities, improve care, and decrease chemotherapy side effects in older patients with cancer.

Research Team

DL

Daneng Li

Principal Investigator

City of Hope Medical Center

Eligibility Criteria

This trial is for older adults with any stage of solid tumor cancer who are about to start a new chemotherapy regimen. Participants must speak English, Spanish, or Chinese and be able to give written consent. It's not open to those who aren't fluent in these languages.

Inclusion Criteria

I am about to start a new chemotherapy treatment.
I have been diagnosed with a solid tumor cancer.
Able to provide written informed consent

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Geriatric Assessment

Participants undergo a geriatric assessment to identify vulnerabilities and potential referrals

1-2 weeks
1 visit (in-person or via Telehealth)

Treatment

Participants receive chemotherapy with interventions based on geriatric assessment results

6 months
Regular visits (in-person or via Telehealth)

Follow-up

Participants are monitored for safety, effectiveness, and quality of life after treatment

6 months

Treatment Details

Interventions

  • Comprehensive Geriatric Assessment
Trial Overview The study tests if assessing an older patient's overall health before chemotherapy can predict treatment side effects and identify vulnerabilities. Patients will complete questionnaires and undergo comprehensive assessments covering function, comorbidities, psychology, social support, nutrition, and cognition.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (geriatric assessment-driven treatment)Experimental Treatment4 Interventions
Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
Group II: Arm II (standard of care)Active Control3 Interventions
Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.

Find a Clinic Near You

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials
614
Recruited
1,924,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a study of 292 cancer patients aged 65 and older, a high prevalence of geriatric conditions was found, including instrumental ADL impairment (78%) and depressive symptoms (65%), indicating significant health challenges in this population.
Mortality rates were notably high, with 38% of patients dying within 3 months and 64% within 12 months, but mortality was primarily linked to cancer-related factors rather than geriatric conditions, suggesting that cancer severity may be a more critical determinant of outcomes.
The value of a comprehensive geriatric assessment for patient care in acutely hospitalized older patients with cancer.Hamaker, ME., Buurman, BM., van Munster, BC., et al.[2021]
In a study of 110 patients aged 70 and older undergoing Comprehensive Geriatric Assessment (CGA), 70% were found to have multiple health issues, highlighting the complexity of treating older cancer patients.
Despite the use of CGA and oncologist clinical judgment, neither method was effective in predicting unfavorable outcomes from cancer treatment, with a significant discrepancy noted between the two assessments in nearly 39% of cases.
Predicting outcome in older patients with cancer: Comprehensive geriatric assessment and clinical judgment.Versteeg, KS., Looijaard, SMLM., Slee-Valentijn, MS., et al.[2021]
A comprehensive geriatric assessment (CGA) is increasingly recognized as a valuable tool for evaluating the overall health of elderly cancer patients, which can aid in treatment decisions and predict outcomes.
While CGA shows promise in oncology, there are practical challenges in its application that may affect its integration into standard clinical practice.
The comprehensive geriatric assessment in oncology: promises, pitfalls, and practicalities.Horgan, AM., Knox, JJ., Alibhai, SM.[2015]

References

The value of a comprehensive geriatric assessment for patient care in acutely hospitalized older patients with cancer. [2021]
Predicting outcome in older patients with cancer: Comprehensive geriatric assessment and clinical judgment. [2021]
The comprehensive geriatric assessment in oncology: promises, pitfalls, and practicalities. [2015]
How to incorporate geriatric assessment in clinical decision-making for older patients with cancer. An implementation study. [2020]
[Oncogeriatrics: an attempt to operational definition]. [2009]
[Risk assessment in medical geriatric oncology]. [2019]
Feasibility of geriatric assessment in community oncology clinics. [2016]
[Should older patients with cancer visit a geriatrician as well? The value of geriatric assessments]. [2020]
What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. [2022]
Six independent domains are defined by geriatric assessment in elderly cancer patients. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Use of geriatric assessment for older adults in the oncology setting: a systematic review. [2022]
[Current views in geriatric oncology]. [2009]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security